Organon & Co.
NYSE:OGN Rapporto sulle azioni
Organon Performance dei guadagni passati
Il passato criteri di controllo 4/6 Gli utili di Organon sono diminuiti a un tasso medio annuo di -29.7%, mentre il settore Pharmaceuticals ha visto gli utili crescere a un tasso medio annuo di 2.1%. I ricavi sono cresciuti diminuire a un tasso medio annuo di 2.4%. Il ritorno sul capitale proprio di Organon è 263.9% e ha margini netti di 20.3%.
Informazioni chiave
-29.7%
Tasso di crescita degli utili
-30.0%
Tasso di crescita dell'EPS
Pharmaceuticals Crescita del settore 6.0% Tasso di crescita dei ricavi -2.4% Rendimento del capitale proprio 263.9% Margine netto 20.3% Ultimo aggiornamento sui guadagni 30 Sep 2024
Aggiornamenti sulle prestazioni recenti
Third quarter 2024 earnings released: EPS: US$1.39 (vs US$0.23 in 3Q 2023) Nov 01
Organon & Co. to Report Q3, 2024 Results on Oct 31, 2024 Oct 09
Second quarter 2024 earnings released: EPS: US$0.76 (vs US$0.95 in 2Q 2023) Aug 07
Organon & Co. to Report Q2, 2024 Results on Aug 06, 2024 Jul 10
Organon's (NYSE:OGN) Solid Profits Have Weak Fundamentals May 10
First quarter 2024 earnings released: EPS: US$0.79 (vs US$0.70 in 1Q 2023) May 03
Mostra tutti gli aggiornamenti
Organon & Co. Updates on FDA Review of VTAMA (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older Nov 05
The Organon & Co. (NYSE:OGN) Third-Quarter Results Are Out And Analysts Have Published New Forecasts Nov 04
Third quarter dividend of US$0.28 announced Nov 03 Organon & Co. Revises Earnings Guidance for the Full Year 2024
Third quarter 2024 earnings released: EPS: US$1.39 (vs US$0.23 in 3Q 2023) Nov 01
Organon & Co. (NYSE:OGN) completed the acquisition of Dermavant Sciences Ltd. from Roivant Sciences Ltd. (NasdaqGS:ROIV) and others. Oct 28
Organon & Co. to Report Q3, 2024 Results on Oct 31, 2024 Oct 09
Shanghai Henlius Biotech, Inc. and Organon Announces Phase 3 Comparative Clinical Study of Perjeta®? (pertuzumab) Biosimilar Candidate HLX11 Oct 01
Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis Sep 19 Organon & Co. (NYSE:OGN) agreed to acquire Dermavant Sciences Ltd. from Roivant Sciences Ltd. (NasdaqGS:ROIV) and others for approximately $1.2 billion. Sep 18
These 4 Measures Indicate That Organon (NYSE:OGN) Is Using Debt In A Risky Way Sep 13
Organon & Co.: Cheap With Caveats Aug 22
Organon (NYSE:OGN) Will Pay A Dividend Of $0.28 Aug 09
Second quarter 2024 earnings released: EPS: US$0.76 (vs US$0.95 in 2Q 2023) Aug 07
Insufficient Growth At Organon & Co. (NYSE:OGN) Hampers Share Price Aug 07 Organon & Co. Affirms Revenue Guidance for the Full Year 2024
Investor sentiment deteriorates as stock falls 16% Aug 06
Organon: Upcoming Q2 Earnings Can Sustain Upward Momentum Jul 30
Organon & Co. to Report Q2, 2024 Results on Aug 06, 2024 Jul 10
Organon & Co.'s (NYSE:OGN) CEO Might Not Expect Shareholders To Be So Generous This Year May 29
Shanghai Henlius Biotech, Inc. and Organon Announces That the European Medicines Agency Has Validated the Marketing Authorization Applications (Maas) for Hlx14 May 25
Organon's (NYSE:OGN) Solid Profits Have Weak Fundamentals May 10
Four Reasons Why Organon Stock Is A Good Buy May 07
First quarter dividend of US$0.28 announced May 05
First quarter 2024 earnings released: EPS: US$0.79 (vs US$0.70 in 1Q 2023) May 03 Organon & Co. Provides Earnings Guidance for the Year 2023
Organon & Co., Annual General Meeting, Jun 04, 2024 Apr 28
Little Excitement Around Organon & Co.'s (NYSE:OGN) Earnings Apr 21
Organon & Co. to Report Q1, 2024 Results on May 02, 2024 Apr 09
CEO & Director exercised options and sold US$628k worth of stock Apr 04
CEO & Director exercised options and sold US$729k worth of stock Mar 03
Organon Stock Is Still Worth A Look Feb 24 US Department of Veterans Affairs (VA) Selects Organon & Co.'s HADLIMA, Replacing HUMIRA on Its National Formulary
Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28 Feb 19
Fourth quarter dividend of US$0.28 announced Feb 19
Full year 2023 earnings: EPS exceeds analyst expectations Feb 16
Organon Q4 And Full Year 2023 Earnings Review - Positive Updates At Last Feb 16 Organon & Co. Declares Quarterly Dividend, Payable on March 14, 2024
Organon & Co. to Report Q4, 2023 Results on Feb 15, 2024 Feb 02
Investor sentiment improves as stock rises 18% Jan 10
Organon’S Xaciato (Clindamycin Phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis in Females Aged 12 and Older Jan 10
Organon: What I'm Looking For In This 8% Yield In 2024 Jan 03
High Risk, High Reward: Why 8.5%-Yielding Organon Could Be Up To 90% Undervalued Dec 19
Organon & Co. Announces Departure of Sandra Milligan as Head of Research and Development Effective January 5, 2024 Dec 06
Organon: It's Darkest Before The Dawn Nov 30
Investor sentiment deteriorates as stock falls 16% Nov 11
Consensus EPS estimates fall by 22% Nov 10
Samsung Bioepis & Organon Announces FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (Adalimumab-bwwd) Nov 08
Organon: Poor Q3 Earnings Make Bear Case, But Dividend Is Saving Grace Nov 07
Organon (NYSE:OGN) Has Affirmed Its Dividend Of $0.28 Nov 05
Price target decreased by 13% to US$24.56 Nov 03
Organon & Co. Declares a Quarterly Dividend, Payable on December 14, 2023 Nov 03
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Nov 02
Organon & Co. to Report Q3, 2023 Results on Nov 02, 2023 Oct 20
Organon: The Federal Reserve Black Swan (Rating Upgrade) Oct 04
Organon & Co.(NYSE:OGN) dropped from FTSE All-World Index (USD) Sep 18
Organon Announces First Real-World Observational Study of the JADA® System Sep 15
6% Yield And Significantly Undervalued: A Closer Look At Organon Sep 10
Organon Announces Two Leadership Appointments Sep 06
Organon & Co. Revises Earnings Guidance for the Full Year 2023 Aug 10
Organon Q2 2023 Earnings Review: Incremental Growth With A Slather Of Risk Aug 10
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 08
Samsung Bioepis & Organon Announces Topline Results from Interchangeability Study of SB5 Humira Biosimilar Aug 02
Price target decreased by 7.8% to US$28.38 Jul 31
Organon & Co. to Report Q2, 2023 Results on Aug 08, 2023 Jul 18
Organon & Co.: A Tough Spot To Be In Right Now Jul 16
Organon & Co. & Samsungbioepis Co,.Ltd Announces US Launch of Humira Biosimilar Hadlima (adalimumab-Bwwd) in Multiple Presentations Consistent with Originator Jul 03
Consensus EPS estimates fall by 16% May 12 Organon & Co. Declares Guidance Quarterly Dividend, Payable on June 15, 2023
First quarter 2023 earnings: EPS misses analyst expectations May 05
CEO & Director exercised options and sold US$275k worth of stock Apr 06
CEO & Director exercised options and sold US$160k worth of stock Mar 03
Organon goes ex-dividend tomorrow Feb 23
Organon & Co. (NYSE:OGN) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock? Feb 19
Full year 2022 earnings: EPS misses analyst expectations Feb 17 Organon Declares Quarterly Dividend, Payable on March 16, 2023
Organon & Co. to Report Q4, 2022 Results on Feb 16, 2023 Feb 07
Is There Anything Organic Or Interesting About Organon? Feb 07
Organon & Co. Appoints Kirke Weaver as General Counsel and Corporate Secretary, Effective January 1, 2023 Dec 13
Organon Canada Launches Ontruzant®, A Biosimilar of the Reference Biologic Herceptin®, Providing Patients in Canada with Certain Breast and Gastric Cancers with an Additional Therapeutic Option At A Lower Cost Nov 15
Organon goes ex-dividend tomorrow Nov 09
Organon's (NYSE:OGN) Dividend Will Be $0.28 Nov 08
Organon Canada Launches Aybintio Providing New Option at Reduced Cost for Canadians Living with Certain Aggressive Forms of Cancer Nov 08
Take Care Before Diving Into The Deep End On Organon & Co. (NYSE:OGN) Nov 05
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 04 Organon & Co. Revises Earnings Guidance for the Full Year 2022
Ripartizione dei ricavi e delle spese
Come Organon guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate NYSE:OGN Ricavi, spese e utili (USD Millions ) Data Ricavi Guadagni Spese G+A Spese di R&S 30 Sep 24 6,409 1,301 1,757 473 30 Jun 24 6,346 1,000 1,873 499 31 Mar 24 6,347 1,047 1,887 511 31 Dec 23 6,263 1,023 1,891 528 30 Sep 23 6,150 585 1,892 536 30 Jun 23 6,168 754 1,794 526 31 Mar 23 6,145 746 1,766 504 31 Dec 22 6,174 917 1,702 471 30 Sep 22 6,292 1,011 1,717 439 30 Jun 22 6,355 1,107 1,665 398 31 Mar 22 6,365 1,304 1,658 368 31 Dec 21 6,304 1,351 1,669 339 30 Sep 21 6,314 1,525 1,620 289 30 Jun 21 6,327 1,762 1,553 257 31 Mar 21 6,258 1,917 1,421 232 31 Dec 20 6,532 2,256 1,356 210 31 Dec 19 7,777 3,306 1,443 220 31 Dec 18 9,777 2,153 1,956 365 31 Dec 17 10,500 1,801 2,250 355
Guadagni di qualità: OGN ha guadagni di alta qualità .
Margine di profitto in crescita: Gli attuali margini di profitto netti di OGN (20.3%) OGN sono più alti rispetto allo scorso anno (9.5%).
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: Gli utili di OGN sono diminuiti del 29.7% all'anno negli ultimi 5 anni.
Accelerare la crescita: La crescita degli utili di OGN nell'ultimo anno ( 122.4% ) supera la media quinquennale ( -29.7% all'anno).
Guadagni vs Settore: La crescita degli utili OGN nell'ultimo anno ( 122.4% ) ha superato la percentuale del settore Pharmaceuticals 54.6%.
Rendimento del capitale proprio
ROE elevato: Sebbene il Return on Equity ( 263.89% ) di OGN sia eccezionale , questa metrica è distorta a causa del loro elevato livello di debito.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
